Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more
Emcure Pharmaceuticals Ltd (EMCURE) - Total Assets
Latest total assets as of September 2025: ₹93.93 Billion INR
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) holds total assets worth ₹93.93 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Emcure Pharmaceuticals Ltd - Total Assets Trend (2022–2025)
This chart illustrates how Emcure Pharmaceuticals Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Emcure Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Emcure Pharmaceuticals Ltd's total assets of ₹93.93 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 1.5% |
| Accounts Receivable | ₹20.55 Billion | 25.0% |
| Inventory | ₹19.32 Billion | 23.5% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹5.79 Billion | 7.0% |
| Goodwill | ₹3.68 Billion | 4.5% |
Asset Composition Trend (2022–2025)
This chart illustrates how Emcure Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Emcure Pharmaceuticals Ltd's current assets represent 55.3% of total assets in 2025, a decrease from 56.5% in 2022.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, up from 1.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 5.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 25.0% of total assets.
Emcure Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Emcure Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Emcure Pharmaceuticals Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Emcure Pharmaceuticals Ltd generates 0.95x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Emcure Pharmaceuticals Ltd generates $8.28 in net profit.
Emcure Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.57 | 1.34 |
| Quick Ratio | 0.90 | 0.95 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹19.19 Billion | ₹ 16.24 Billion | ₹ 9.90 Billion |
Emcure Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Emcure Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.83 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | ₹82.33 Billion |
| Market Capitalization | $644.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Emcure Pharmaceuticals Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Emcure Pharmaceuticals Ltd's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Emcure Pharmaceuticals Ltd (2022–2025)
The table below shows the annual total assets of Emcure Pharmaceuticals Ltd from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹82.33 Billion | +5.46% |
| 2024-03-31 | ₹78.06 Billion | +16.99% |
| 2023-03-31 | ₹66.73 Billion | +10.04% |
| 2022-03-31 | ₹60.63 Billion | -- |